- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Michael Thorpy on Misconceptions in the Treatment of Narcolepsy-Related EDS
Michael Thorpy, MD, director, Sleep-Wake Disorders Center, Montefiore, and professor, Neurology, Albert Einstein College of Medicine, speaks about common misconceptions within the treatment of narcolepsy-related excessive daytime sleepiness, and how combination therapy may play a role.
A misconception within the treatment of narcolepsy-related excessive daytime sleepiness is that it can be controlled by one therapy, but combination therapy is likely needed to address the full scope of disease burden, said Michael Thorpy, MD, director, Sleep-Wake Disorders Center, Montefiore, and professor, Neurology, Albert Einstein College of Medicine.
Transcript
What is a common misconception within the treatment of narcolepsy-related excessive daytime sleepiness?
I think that most physicians think that the excessive sleepiness in narcolepsy can be controlled entirely with 1 medication. I think what we're finding is that the majority of patients need multiple medications—2, or in some cases, even 3 medications.
So, the important thing about treating sleepiness is to get patients as much control as possible, so the patient's quality of life, occupation, and education are not adversely affected by the narcolepsy. I think one of the misconceptions that physicians have is that they might just prescribe one medication and reach a sort of maximum dosage, and think that that's the end of treatment. But I think we need to go a little bit further to try to produce treatments that really make major differences to patients and this often requires a combination therapy.
Hospital Participation in Medicare ACOs: No Change in Admission Practices and Spending
August 19th 2025Hospital accountable care organization (ACO) participation did not impact emergency department admission rates, length of stay, or costs, suggesting limited effectiveness in reducing spending for unplanned admissions and challenging hospital-led ACO cost-saving strategies.
Read More
Roflumilast Cream 0.05% Durable, Safe for Younger Pediatric Patients
August 15th 2025The INTEGUMENT-OLE study is an open-label extension analysis that followed a primary investigation from the phase 3 INTEGUMENT-PED trial, which investigated the efficacy and safety of once-daily roflumilast cream 0.05% for atopic dermatitis in children aged 2 to 5 years.
Read More
PCPs Have Unique Opportunity to Detect, Manage CKD
August 14th 2025As the prevalence of chronic kidney disease (CKD) continues to rise, empowering primary care providers (PCPs) with the tools, training, and collaborative frameworks needed for optimal management is a public health priority, emphasize the researchers.
Read More
